Incorporation of FLT3 inhibitor to upfront induction and consolidation chemotherapy; combination of FLT3 inhibitor with low intensity regimen as salvage treatment and the use of FLT3 inhibitor as post-HSCT maintenance may improve treatment outcome of this AML subtype. This evidence concerns the gene FLT3 and acute myeloid leukemia.